Market research
CYP.AU Cynata Therapeutics Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.1
- Dividend yield
- Not available
- Beta
- 1.1
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000CYP7
- Market cap
- 3M
- P/E ratio
- Not available
- Analyst target
- 1.1
- Dividend yield
- Not available
- Beta
- 1.1
About
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYP.AU discussion.
5 years, 5 months ago
Cynata Therapeutics Limited is currently in a long term downtrend where the price is trading 23.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Cynata Therapeutics Limited's total revenue sank by 8.5% to $33K since the same quarter in the previous year.
Its net income has dropped by 89.9% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 83.1% to $-2M since the same quarter in the previous year.
Based on the above factors, Cynata Therapeutics Limited gets an overall score of 1/5.